vs
Amarin Corp plc（AMRN）与OCTAVE SPECIALTY GROUP INC（OSG）财务数据对比。点击上方公司名可切换其他公司
OCTAVE SPECIALTY GROUP INC的季度营收约是Amarin Corp plc的2.3倍（$104.2M vs $45.1M），OCTAVE SPECIALTY GROUP INC净利率更高（-6.6% vs -23.3%，领先16.7%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 7.0%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
AMRN vs OSG — 直观对比
营收规模更大
OSG
是对方的2.3倍
$45.1M
营收增速更快
OSG
高出59.0%
7.0%
净利率更高
OSG
高出16.7%
-23.3%
两年增速更快
OSG
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $104.2M |
| 净利润 | $-10.5M | $-6.9M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | — |
| 净利率 | -23.3% | -6.6% |
| 营收同比 | 7.0% | 66.0% |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | — | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNOSG
| Q1 26 | $45.1M | $104.2M | ||
| Q4 25 | $49.2M | $66.9M | ||
| Q3 25 | $49.7M | $66.6M | ||
| Q2 25 | $72.7M | $55.0M | ||
| Q1 25 | $42.0M | $62.8M | ||
| Q4 24 | $62.3M | $65.2M | ||
| Q3 24 | $42.3M | $70.0M | ||
| Q2 24 | $67.5M | $51.0M |
净利润AMRNOSG
| Q1 26 | $-10.5M | $-6.9M | ||
| Q4 25 | $-1.2M | $-29.7M | ||
| Q3 25 | $-7.7M | $-112.6M | ||
| Q2 25 | $-14.1M | $-72.7M | ||
| Q1 25 | $-15.7M | $-44.7M | ||
| Q4 24 | $-48.6M | $-20.9M | ||
| Q3 24 | $-25.1M | $-27.5M | ||
| Q2 24 | $1.5M | $-750.0K |
毛利率AMRNOSG
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNOSG
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | -76.7% | ||
| Q3 25 | -22.4% | -48.2% | ||
| Q2 25 | -22.0% | -41.8% | ||
| Q1 25 | -39.9% | -24.1% | ||
| Q4 24 | -84.3% | -55.5% | ||
| Q3 24 | -59.5% | -29.7% | ||
| Q2 24 | -0.8% | -28.9% |
净利率AMRNOSG
| Q1 26 | -23.3% | -6.6% | ||
| Q4 25 | -2.5% | -73.8% | ||
| Q3 25 | -15.6% | -169.1% | ||
| Q2 25 | -19.4% | -132.3% | ||
| Q1 25 | -37.4% | -71.3% | ||
| Q4 24 | -78.0% | -55.1% | ||
| Q3 24 | -59.4% | -39.3% | ||
| Q2 24 | 2.3% | -1.5% |
每股收益（稀释后）AMRNOSG
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.00 | $-0.82 | ||
| Q3 25 | $-0.02 | $-2.35 | ||
| Q2 25 | $-0.03 | $-1.54 | ||
| Q1 25 | $-0.04 | $-1.22 | ||
| Q4 24 | $-0.12 | $-11.75 | ||
| Q3 24 | $-0.06 | $-0.63 | ||
| Q2 24 | $0.00 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | — |
| 总债务越低越好 | — | $117.1M |
| 股东权益账面价值 | — | $833.6M |
| 总资产 | $645.8M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资AMRNOSG
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $146.4M | ||
| Q3 25 | $286.6M | $27.5M | ||
| Q2 25 | $298.7M | $22.5M | ||
| Q1 25 | $281.8M | $34.1M | ||
| Q4 24 | $294.2M | $157.2M | ||
| Q3 24 | $305.7M | $40.8M | ||
| Q2 24 | $306.7M | $14.6M |
总债务AMRNOSG
| Q1 26 | — | $117.1M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $518.0M | ||
| Q2 24 | — | $515.0M |
股东权益AMRNOSG
| Q1 26 | — | $833.6M | ||
| Q4 25 | $459.3M | $715.8M | ||
| Q3 25 | $458.9M | $843.4M | ||
| Q2 25 | $464.9M | $859.8M | ||
| Q1 25 | $473.7M | $852.2M | ||
| Q4 24 | $486.2M | $798.4M | ||
| Q3 24 | $531.4M | $1.5B | ||
| Q2 24 | $551.9M | $1.4B |
总资产AMRNOSG
| Q1 26 | $645.8M | $2.3B | ||
| Q4 25 | $670.8M | $2.2B | ||
| Q3 25 | $659.8M | $2.1B | ||
| Q2 25 | $670.1M | $8.5B | ||
| Q1 25 | $655.7M | $8.3B | ||
| Q4 24 | $685.3M | $8.1B | ||
| Q3 24 | $750.6M | $9.3B | ||
| Q2 24 | $799.9M | $8.2B |
负债/权益比AMRNOSG
| Q1 26 | — | 0.14× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
